These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30967043)

  • 1. The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban.
    Kim B; Jang S; Lee YJ; Park N; Cho YU; Park CJ
    Br J Biomed Sci; 2019 Jul; 76(3):122-128. PubMed ID: 30967043
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
    Harenberg J; Marx S; Krämer R; Giese C; Weiss C
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
    Kubitza D; Becka M; Mück W; Krätzschmar J
    Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.
    Testa S; Morstabilini G; Fattorini A; Galli L; Denti N; D'Angelo A
    Haematologica; 2002 Dec; 87(12):1265-73. PubMed ID: 12495900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.
    Kim B; Jang S; Lee YJ; Park N; Cho YU; Park CJ
    J Thromb Thrombolysis; 2020 Feb; 49(2):245-250. PubMed ID: 31506888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of treatment with vitamin K antagonists: recombinant thromboplastins are more sensitive to factor VII than tissue-extract thromboplastins.
    Biedermann JS; van den Besselaar AM; de Maat MP; Leebeek FW; Kruip MJ
    J Thromb Haemost; 2017 Mar; 15(3):500-506. PubMed ID: 28055147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
    J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents.
    Sermon AM; Smith JM; Maclean R; Kitchen S
    Thromb Haemost; 2010 Apr; 103(4):757-65. PubMed ID: 20174759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.
    Tripodi A; Chantarangkul V; Guinet C; Samama MM
    J Thromb Haemost; 2011 Jan; 9(1):226-8. PubMed ID: 20942848
    [No Abstract]   [Full Text] [Related]  

  • 16. Intrahospital correlation of the international normalized ratio.
    Lazo-Langner A; Villa-Márquez R; Hernández-Hernández D; Rojas-Maya S; Piedras J
    Clin Appl Thromb Hemost; 2009; 15(2):220-4. PubMed ID: 18385150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the measurement uncertainties of the international sensitivity index of 12 thromboplastins through Monte Carlo simulation.
    Lim YK; Kweon OJ; Lee MK; Kim HR
    Thromb Res; 2023 Apr; 224():32-37. PubMed ID: 36812877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
    Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
    Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    Thromb Res; 2015 Feb; 135(2):388-93. PubMed ID: 25555316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.